{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:23:39Z","timestamp":1793298219544,"version":"4.5.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1A2C301016611"],"award-info":[{"award-number":["2021R1A2C301016611"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Oncolytic adenovirus (oAd) elicits antitumor activity by preferential viral replication in cancer cells. However, poor systemic administrability or suboptimal intratumoral retainment of the virus remains a major challenge toward maximizing the antitumor activity of oAd in a clinical environment. To surmount these issues, a variety of non-immunogenic polymers has been used to modify the surface of oAds chemically or physically. Complexation of oAd with polymers can effectively evade the host immune response and reduces nonspecific liver sequestration. The tumor-specific delivery of these complexes can be further improved upon by inclusion of tumor-targeting moieties on the surface. Therefore, modification of the Ad surface using polymers is viewed as a potential strategy to enhance the delivery of Ad via systemic administration. This review aims to provide a comprehensive overview of polymer-complexed Ads, their progress, and future challenges in cancer treatment.<\/jats:p>","DOI":"10.1038\/s41417-022-00469-y","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T08:04:29Z","timestamp":1650441869000},"page":"1321-1331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Challenges and progress toward tumor-targeted therapy by systemic delivery of polymer-complexed oncolytic adenoviruses"],"prefix":"10.1038","volume":"29","author":[{"given":"Thavasyappan","family":"Thambi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JinWoo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A-Rum","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9466-4531","authenticated-orcid":false,"given":"Chae-Ok","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"469_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41416-018-0332-2","volume":"120","author":"A-M Conway","year":"2019","unstructured":"Conway A-M, Mitchell C, Kilgour E, Brady G, Dive C, Cook N. Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the \u2018U\u2019 out of \u2018CUP\u2019. Br J Cancer. 2019;120:141\u201353.","journal-title":"Br J Cancer"},{"key":"469_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","volume":"387","author":"G Attard","year":"2016","unstructured":"Attard G, Parker C, Eeles RA, Schr\u00f6der F, Tomlins SA, Tannock I, et al. Prostate cancer. Lancet. 2016;387:70\u201382.","journal-title":"Lancet"},{"key":"469_CR3","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1021\/acs.biomac.8b00819","volume":"19","author":"TMD Le","year":"2018","unstructured":"Le TMD, Duong HTT, Thambi T, Giang Phan VH, Jeong JH, Lee DS. Bioinspired pH- and temperature-responsive injectable adhesive hydrogels with polyplexes promotes skin wound healing. Biomacromolecules. 2018;19:3536\u201348.","journal-title":"Biomacromolecules"},{"key":"469_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","volume":"18","author":"K Harrington","year":"2019","unstructured":"Harrington K, Freeman DJ, Kelly B, Harper J, Soria J-C. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov. 2019;18:689\u2013706.","journal-title":"Nat Rev Drug Discov"},{"key":"469_CR5","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30:658\u201370.","journal-title":"Nat Biotechnol"},{"key":"469_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0458-z","volume":"6","author":"J Raja","year":"2018","unstructured":"Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS. Oncolytic virus immunotherapy: future prospects for oncology. J Immunother Cancer. 2018;6:140.","journal-title":"J Immunother Cancer"},{"key":"469_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2174\/1568009618666171129221503","volume":"18","author":"L Min","year":"2018","unstructured":"Min L. Oncorine, the world first oncolytic virus medicine and its update in China. Curr Cancer Drug Targets. 2018;18:171\u20136.","journal-title":"Curr Cancer Drug Targets"},{"key":"469_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0158-5","volume":"4","author":"H Rehman","year":"2016","unstructured":"Rehman H, Silk AW, Kane MP, Kaufman HL. Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer. 2016;4:53.","journal-title":"J Immunother Cancer"},{"key":"469_CR9","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14:642\u201362.","journal-title":"Nat Rev Drug Discov"},{"key":"469_CR10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","volume":"18","author":"PK Bommareddy","year":"2018","unstructured":"Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018;18:498\u2013513.","journal-title":"Nat Rev Immunol"},{"key":"469_CR11","doi-asserted-by":"publisher","first-page":"805629","DOI":"10.1155\/2012\/805629","volume":"2012","author":"MS Ferguson","year":"2012","unstructured":"Ferguson MS, Lemoine NR, Wang Y. Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol. 2012;2012:805629\u2013805629.","journal-title":"Adv Virol"},{"key":"469_CR12","doi-asserted-by":"publisher","first-page":"e31454","DOI":"10.1371\/journal.pone.0031454","volume":"7","author":"L Lenaerts","year":"2012","unstructured":"Lenaerts L, van Dam W, Persoons L, Naesens L. Interaction between mouse adenovirus type 1 and cell surface heparan sulfate proteoglycans. PLoS ONE. 2012;7:e31454\u2013e31454.","journal-title":"PLoS ONE"},{"key":"469_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/gt.2011.87","volume":"19","author":"R Alba","year":"2012","unstructured":"Alba R, Bradshaw AC, Mestre-Franc\u00e9s N, Verdier JM, Henaff D, Baker AH. Coagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (Microcebus murinus). Gene Ther. 2012;19:109\u201313.","journal-title":"Gene Ther"},{"key":"469_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2174\/1566523213666131125095046","volume":"13","author":"WSM Wold","year":"2013","unstructured":"Wold WSM, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 2013;13:421\u201333.","journal-title":"Curr Gene Ther"},{"key":"469_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","volume":"17","author":"A Lemos de Matos","year":"2020","unstructured":"Lemos de Matos A, Franco LS, McFadden G. Oncolytic viruses and the immune system: the dynamic duo. Mol Ther Methods Clin Dev. 2020;17:349\u201358.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"469_CR16","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1016\/j.biomaterials.2011.11.020","volume":"33","author":"J Kim","year":"2012","unstructured":"Kim J, Kim P-H, Kim SW, Yun C-O. Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials. Biomaterials. 2012;33:1838\u201350.","journal-title":"Biomaterials"},{"key":"469_CR17","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1586\/erv.09.29","volume":"8","author":"EE Thacker","year":"2009","unstructured":"Thacker EE, Timares L, Matthews QL. Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccines. 2009;8:761\u201377.","journal-title":"Expert Rev Vaccines"},{"key":"469_CR18","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.1039\/D0BM01367F","volume":"8","author":"K Kaygisiz","year":"2020","unstructured":"Kaygisiz K, Synatschke CV. Materials promoting viral gene delivery. Biomater Sci. 2020;8:6113\u201356.","journal-title":"Biomater Sci"},{"key":"469_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/sj.mt.6300321","volume":"16","author":"F Kreppel","year":"2008","unstructured":"Kreppel F, Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther. 2008;16:16\u201329.","journal-title":"Mol Ther"},{"key":"469_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.omto.2021.03.011","volume":"21","author":"C Hill","year":"2021","unstructured":"Hill C, Grundy M, Bau L, Wallington S, Balkaran J, Ramos V, et al. Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus. Mol Ther - Oncolytics. 2021;21:47\u201361.","journal-title":"Mol Ther - Oncolytics"},{"key":"469_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/biomedicines1010003","volume":"1","author":"C Capasso","year":"2013","unstructured":"Capasso C, Hirvinen M, Cerullo V. Beyond gene delivery: strategies to engineer the surfaces of viral vectors. Biomedicines. 2013;1:3\u201316.","journal-title":"Biomedicines"},{"key":"469_CR22","doi-asserted-by":"publisher","first-page":"e12085","DOI":"10.1371\/journal.pone.0012085","volume":"5","author":"IJ Wang","year":"2010","unstructured":"Wang IJ, Jhuang M-C, Chen Y-H, Yeh L-K, Liu C-Y, Young T-H. Chitosan modification of adenovirus to modify transfection efficiency in bovine corneal epithelial cells. PLoS ONE. 2010;5:e12085\u2013e12085.","journal-title":"PLoS ONE"},{"key":"469_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.actbio.2019.06.059","volume":"97","author":"Y Sun","year":"2019","unstructured":"Sun Y, Lv X, Ding P, Wang L, Sun Y, Li S, et al. Exploring the functions of polymers in adenovirus-mediated gene delivery: Evading immune response and redirecting tropism. Acta Biomaterialia. 2019;97:93\u2013104.","journal-title":"Acta Biomaterialia"},{"key":"469_CR24","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/polym12020298","volume":"12","author":"TT Hoang Thi","year":"2020","unstructured":"Hoang Thi TT, Pilkington EH, Nguyen DH, Lee JS, Park KD, Truong NP. The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation. Polymers. 2020;12:298.","journal-title":"Polymers"},{"key":"469_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s12079-018-0492-0","volume":"13","author":"V Gupta","year":"2019","unstructured":"Gupta V, Bhavanasi S, Quadir M, Singh K, Ghosh G, Vasamreddy K, et al. Protein PEGylation for cancer therapy: bench to bedside. J Cell Commun Signal. 2019;13:319\u201330.","journal-title":"J Cell Commun Signal"},{"key":"469_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv drug Deliv Rev. 2016;99:28\u201351.","journal-title":"Adv drug Deliv Rev"},{"key":"469_CR27","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1021\/mp200470c","volume":"9","author":"YR Gokarn","year":"2012","unstructured":"Gokarn YR, McLean M, Laue TM. Effect of PEGylation on protein hydrodynamics. Mol Pharmaceutics. 2012;9:762\u201373.","journal-title":"Mol Pharmaceutics"},{"key":"469_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ymthe.2004.09.015","volume":"11","author":"H Mok","year":"2005","unstructured":"Mok H, Palmer DJ, Ng P, Barry MA. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther. 2005;11:66\u201379.","journal-title":"Mol Ther"},{"key":"469_CR29","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1016\/j.biomaterials.2013.03.004","volume":"34","author":"J Kim","year":"2013","unstructured":"Kim J, Li Y, Kim SW, Lee DS, Yun C-O. Therapeutic efficacy of a systemically delivered oncolytic adenovirus \u2013 Biodegradable polymer complex. Biomaterials. 2013;34:4622\u201331.","journal-title":"Biomaterials"},{"key":"469_CR30","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1089\/10430349950018021","volume":"10","author":"CR O\u2019Riordan","year":"1999","unstructured":"O\u2019Riordan CR, Lachapelle A, Delgado C, Parkes C, Wadsworth SE, Smith AE, et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Human Gene Ther. 1999;10:1349\u201358.","journal-title":"Human Gene Ther"},{"key":"469_CR31","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.1128\/JVI.75.10.4792-4801.2001","volume":"75","author":"MA Croyle","year":"2001","unstructured":"Croyle MA, Chirmule N, Zhang Y, Wilson JM. \u201cStealth\u201d Adenoviruses Blunt Cell-Mediated and Humoral Immune Responses against the Virus and Allow for Significant Gene Expression upon Readministration in the Lung. J Virol. 2001;75:4792.","journal-title":"J Virol"},{"key":"469_CR32","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1089\/104303402760372972","volume":"13","author":"MA Croyle","year":"2002","unstructured":"Croyle MA, Chirmule N, Zhang Y, Wilson JM. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther. 2002;13:1887\u2013900.","journal-title":"Hum Gene Ther"},{"key":"469_CR33","doi-asserted-by":"crossref","unstructured":"Geest BD, Snoeys J, Linthout SV, Lievens J, Collen D. Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. Human Gene Ther. 2005;16: 1439\u201351.","DOI":"10.1089\/hum.2005.16.1439"},{"key":"469_CR34","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/sj.gt.3302441","volume":"12","author":"MA Croyle","year":"2005","unstructured":"Croyle MA, Le HT, Linse KD, Cerullo V, Toietta G, Beaudet A, et al. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther. 2005;12:579\u201387.","journal-title":"Gene Ther"},{"key":"469_CR35","doi-asserted-by":"publisher","first-page":"15021","DOI":"10.1038\/mto.2015.21","volume":"3","author":"TV Nguyen","year":"2016","unstructured":"Nguyen TV, Heller GJ, Barry ME, Crosby CM, Turner MA, Barry MA. Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers. Mol Ther - Oncolytics. 2016;3:15021.","journal-title":"Mol Ther - Oncolytics"},{"key":"469_CR36","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1089\/hum.2009.028","volume":"20","author":"K Doronin","year":"2009","unstructured":"Doronin K, Shashkova EV, May SM, Hofherr SE, Barry MA. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther. 2009;20:975\u201388.","journal-title":"Hum Gene Ther"},{"key":"469_CR37","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jconrel.2007.06.010","volume":"122","author":"J-Q Gao","year":"2007","unstructured":"Gao J-Q, Eto Y, Yoshioka Y, Sekiguchi F, Kurachi S, Morishige T, et al. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J Controlled Release. 2007;122:102\u201310.","journal-title":"J Controlled Release"},{"key":"469_CR38","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/sj.mt.6300306","volume":"16","author":"A Wortmann","year":"2008","unstructured":"Wortmann A, V\u00f6hringer S, Engler T, Corjon S, Schirmbeck R, Reimann J, et al. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol Ther. 2008;16:154\u201362.","journal-title":"Mol Ther"},{"key":"469_CR39","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1089\/hum.2008.091","volume":"19","author":"EA Weaver","year":"2008","unstructured":"Weaver EA, Barry MA. Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses. Hum Gene Ther. 2008;19:1369\u201382.","journal-title":"Hum Gene Ther"},{"key":"469_CR40","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/gt.2009.95","volume":"16","author":"X Yao","year":"2009","unstructured":"Yao X, Yoshioka Y, Morishige T, Eto Y, Watanabe H, Okada Y, et al. Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis. Gene Ther. 2009;16:1395\u2013404.","journal-title":"Gene Ther"},{"key":"469_CR41","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3390\/v2020468","volume":"2","author":"P Wonganan","year":"2010","unstructured":"Wonganan P, Croyle MA. PEGylated adenoviruses: from mice to monkeys. Viruses. 2010;2:468\u2013502.","journal-title":"Viruses"},{"key":"469_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/B978-0-12-398342-8.00002-1","volume":"115","author":"MS Beatty","year":"2012","unstructured":"Beatty MS, Curiel DT. Chapter two\u2013adenovirus strategies for tissue-specific targeting. Adv Cancer Res. 2012;115:39\u201367.","journal-title":"Adv Cancer Res"},{"key":"469_CR43","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jconrel.2016.06.022","volume":"235","author":"L Krutzke","year":"2016","unstructured":"Krutzke L, Prill JM, Engler T, Schmidt CQ, Xu Z, Byrnes AP, et al. Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: preventing vector clearance and preserving infectivity. J Controlled Release. 2016;235:379\u201392.","journal-title":"J Controlled Release"},{"key":"469_CR44","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/sj.gt.3301389","volume":"8","author":"KD Fisher","year":"2001","unstructured":"Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 2001;8:341\u20138.","journal-title":"Gene Ther"},{"key":"469_CR45","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/sj.gt.3302295","volume":"11","author":"NK Green","year":"2004","unstructured":"Green NK, Herbert CW, Hale SJ, Hale AB, Mautner V, Harkins R, et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 2004;11:1256\u201363.","journal-title":"Gene Ther"},{"key":"469_CR46","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1080\/10611860701501014","volume":"15","author":"KD Fisher","year":"2007","unstructured":"Fisher KD, Green NK, Hale A, Subr V, Ulbrich K, Seymour LW. Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy. J Drug Target. 2007;15:546\u201351.","journal-title":"J Drug Target"},{"key":"469_CR47","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/156652311796150372","volume":"11","author":"YS Ahi","year":"2011","unstructured":"Ahi YS, Bangari DS, Mittal SK. Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther. 2011;11:307\u201320.","journal-title":"Curr Gene Ther"},{"key":"469_CR48","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1021\/acs.macromol.6b00422","volume":"49","author":"JR Lovett","year":"2016","unstructured":"Lovett JR, Ratcliffe LPD, Warren NJ, Armes SP, Smallridge MJ, Cracknell RB, et al. A robust cross-linking strategy for block copolymer worms prepared via polymerization-induced self-assembly. Macromolecules. 2016;49:2928\u201341.","journal-title":"Macromolecules"},{"key":"469_CR49","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1021\/acs.bioconjchem.9b00456","volume":"30","author":"AK Pearce","year":"2019","unstructured":"Pearce AK, O\u2019Reilly RK. Insights into active targeting of nanoparticles in drug delivery: advances in clinical studies and design considerations for cancer nanomedicine. Bioconjugate Chem. 2019;30:2300\u201311.","journal-title":"Bioconjugate Chem"},{"key":"469_CR50","doi-asserted-by":"crossref","unstructured":"Large DE, Soucy JR, Hebert J, Auguste DT. Advances in receptor-mediated, tumor-targeted drug delivery. Adv. Ther. 2019;2:1800091.","DOI":"10.1002\/adtp.201800091"},{"key":"469_CR51","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1038\/am.2014.12","volume":"6","author":"Q Liu","year":"2014","unstructured":"Liu Q, Jin C, Wang Y, Fang X, Zhang X, Chen Z, et al. Aptamer-conjugated nanomaterials for specific cancer cell recognition and targeted cancer therapy. NPG Asia Mater. 2014;6:e95\u2013e95.","journal-title":"NPG Asia Mater"},{"key":"469_CR52","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/jgm.699","volume":"7","author":"Y Eto","year":"2005","unstructured":"Eto Y, Gao J-Q, Sekiguchi F, Kurachi S, Katayama K, Maeda M, et al. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med. 2005;7:604\u201312.","journal-title":"J Gene Med"},{"key":"469_CR53","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/mt.2011.112","volume":"19","author":"X Yao","year":"2011","unstructured":"Yao X, Yoshioka Y, Morishige T, Eto Y, Narimatsu S, Kawai Y, et al. Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy. Mol Ther. 2011;19:1619\u201325.","journal-title":"Mol Ther"},{"key":"469_CR54","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.cgh.2009.07.039","volume":"7","author":"S Pandol","year":"2009","unstructured":"Pandol S, Edderkaoui M, Gukovsky I, Lugea A, Gukovskaya A. Desmoplasia of pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2009;7:S44\u2013S47.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"469_CR55","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s00726-017-2430-5","volume":"49","author":"X Yin","year":"2017","unstructured":"Yin X, Wang M, Wang H, Deng H, He T, Tan Y, et al. Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma. Amino Acids. 2017;49:1325\u201335.","journal-title":"Amino Acids"},{"key":"469_CR56","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.jconrel.2015.10.015","volume":"220","author":"Y Na","year":"2015","unstructured":"Na Y, Choi J-W, Kasala D, Hong J, Oh E, Li Y, et al. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model. J Controlled Release. 2015;220:766\u201382.","journal-title":"J Controlled Release"},{"key":"469_CR57","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1530\/JOE-14-0393","volume":"223","author":"YJ Ono","year":"2014","unstructured":"Ono YJ, Terai Y, Tanabe A, Hayashi A, Hayashi M, Yamashita Y, et al. Decorin induced by progesterone plays a crucial role in suppressing endometriosis. J Endocrinol. 2014;223:203\u201316.","journal-title":"J Endocrinol"},{"key":"469_CR58","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1146\/annurev.biochem.77.032207.120833","volume":"78","author":"MD Shoulders","year":"2009","unstructured":"Shoulders MD, Raines RT. Collagen structure and stability. Annu Rev Biochem. 2009;78:929\u201358.","journal-title":"Annu Rev Biochem"},{"key":"469_CR59","doi-asserted-by":"publisher","first-page":"5480","DOI":"10.18632\/oncotarget.23869","volume":"9","author":"W Zhang","year":"2018","unstructured":"Zhang W, Ge Y, Cheng Q, Zhang Q, Fang L, Zheng J. Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment. Oncotarget. 2018;9:5480\u201391.","journal-title":"Oncotarget"},{"key":"469_CR60","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1016\/j.biomaterials.2010.10.031","volume":"32","author":"P-H Kim","year":"2011","unstructured":"Kim P-H, Sohn J-H, Choi J-W, Jung Y, Kim SW, Haam S, et al. Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin. Biomaterials. 2011;32:2314\u201326.","journal-title":"Biomaterials"},{"key":"469_CR61","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1006\/mthe.2002.0568","volume":"5","author":"D Oupicky","year":"2002","unstructured":"Oupicky D, Ogris M, Howard KA, Dash PR, Ulbrich K, Seymour LW. Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation. Mol Ther. 2002;5:463\u201372.","journal-title":"Mol Ther"},{"key":"469_CR62","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1021\/acs.chemrev.5b00589","volume":"116","author":"K Ulbrich","year":"2016","unstructured":"Ulbrich K, Hol\u00e1 K, \u0160ubr V, Bakandritsos A, Tu\u010dek J, Zbo\u0159il R. Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies. Chem Rev. 2016;116:5338\u2013431.","journal-title":"Chem Rev"},{"key":"469_CR63","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1089\/hum.2008.167","volume":"20","author":"J Morrison","year":"2009","unstructured":"Morrison J, et al. Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer. Hum Gene Ther. 2009;20:239\u201351.","journal-title":"Hum Gene Ther"},{"key":"469_CR64","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/wdev.176","volume":"4","author":"DM Ornitz","year":"2015","unstructured":"Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev. Biol. 2015;4:215\u201366.","journal-title":"Wiley Interdiscip Rev Dev. Biol"},{"key":"469_CR65","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1080\/19420862.2019.1624127","volume":"11","author":"M Cao","year":"2019","unstructured":"Cao M, De Mel N, Jiao Y, Howard J, Parthemore C, Korman S, et al. Site-specific antibody-drug conjugate heterogeneity characterization and heterogeneity root cause analysis. MAbs. 2019;11:1064\u201376.","journal-title":"MAbs"},{"key":"469_CR66","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/jgm.1121","volume":"10","author":"NK Green","year":"2008","unstructured":"Green NK, Morrison J, Hale S, Briggs SS, Stevenson M, Subr V, et al. Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. J Gene Med. 2008;10:280\u20139.","journal-title":"J Gene Med"},{"key":"469_CR67","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.biomaterials.2018.09.008","volume":"185","author":"HTT Duong","year":"2018","unstructured":"Duong HTT, Yin Y, Thambi T, Nguyen TL, Giang Phan VH, Lee MS, et al. Smart vaccine delivery based on microneedle arrays decorated with ultra-pH-responsive copolymers for cancer immunotherapy. Biomaterials. 2018;185:13\u201324.","journal-title":"Biomaterials"},{"key":"469_CR68","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jconrel.2017.11.025","volume":"269","author":"HTT Duong","year":"2018","unstructured":"Duong HTT, Kim NW, Thambi T, Giang Phan VH, Lee MS, Yin Y, et al. Microneedle arrays coated with charge reversal pH-sensitive copolymers improve antigen presenting cells-homing DNA vaccine delivery and immune responses. J Controlled Release. 2018;269:225\u201334.","journal-title":"J Controlled Release"},{"key":"469_CR69","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1006\/mthe.2000.0142","volume":"2","author":"S-O Han","year":"2000","unstructured":"Han S-O, Mahato RI, Sung YK, Kim SW. Development of biomaterials for gene therapy. Mol Ther. 2000;2:302\u201317.","journal-title":"Mol Ther"},{"key":"469_CR70","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.addr.2011.12.011","volume":"64","author":"J-W Choi","year":"2012","unstructured":"Choi J-W, Lee J-S, Kim SW, Yun C-O. Evolution of oncolytic adenovirus for cancer treatment. Adv Drug Deliv Rev. 2012;64:720\u20139.","journal-title":"Adv Drug Deliv Rev"},{"key":"469_CR71","doi-asserted-by":"publisher","first-page":"9328","DOI":"10.1016\/j.biomaterials.2011.08.066","volume":"32","author":"P-H Kim","year":"2011","unstructured":"Kim P-H, Kim J, Kim T-I, Nam HY, Yockman JW, Kim M, et al. Bioreducible polymer-conjugated oncolytic adenovirus for hepatoma-specific therapy via systemic administration. Biomaterials. 2011;32:9328\u201342.","journal-title":"Biomaterials"},{"key":"469_CR72","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/aps.2015.92","volume":"36","author":"X-X Sun","year":"2015","unstructured":"Sun X-X, Yu Q. Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacologica Sin. 2015;36:1219\u201327.","journal-title":"Acta Pharmacologica Sin"},{"key":"469_CR73","doi-asserted-by":"publisher","first-page":"9536","DOI":"10.1016\/j.biomaterials.2011.08.069","volume":"32","author":"C-HK Wang","year":"2011","unstructured":"Wang C-HK, Chan LW, Johnson RN, Chu DSH, Shi J, Schellinger JG, et al. The transduction of Coxsackie and Adenovirus Receptor-negative cells and protection against neutralizing antibodies by HPMA-co-oligolysine copolymer-coated adenovirus. Biomaterials. 2011;32:9536\u201345.","journal-title":"Biomaterials"},{"key":"469_CR74","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1021\/acs.bioconjchem.9b00189","volume":"30","author":"N Francini","year":"2019","unstructured":"Francini N, Cochrane D, Illingworth S, Purdie L, Mantovani G, Fisher K, et al. Polyvalent diazonium polymers provide efficient protection of oncolytic adenovirus enadenotucirev from neutralizing antibodies while maintaining biological activity in vitro and in vivo. Bioconjugate Chem. 2019;30:1244\u201357.","journal-title":"Bioconjugate Chem"},{"key":"469_CR75","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1021\/acs.bioconjchem.5b00357","volume":"26","author":"J-W Choi","year":"2015","unstructured":"Choi J-W, Kim J, Bui QN, Li Y, Yun C-O, Lee DS, et al. Tuning surface charge and pegylation of biocompatible polymers for efficient delivery of nucleic acid or adenoviral vector. Bioconjugate Chem. 2015;26:1818\u201329.","journal-title":"Bioconjugate Chem"},{"key":"469_CR76","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1016\/j.biomaterials.2014.03.060","volume":"35","author":"C-H Lee","year":"2014","unstructured":"Lee C-H, Kasala D, Na Y, Lee MS, Kim SW, Jeong JH, et al. Enhanced therapeutic efficacy of an adenovirus-PEI-bile-acid complex in tumors with low coxsackie and adenovirus receptor expression. Biomaterials. 2014;35:5505\u201316.","journal-title":"Biomaterials"},{"key":"469_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s40824-019-0156-z","volume":"23","author":"YK Sung","year":"2019","unstructured":"Sung YK, Kim SW. Recent advances in the development of gene delivery systems. Biomater Res. 2019;23:8.","journal-title":"Biomater Res"},{"key":"469_CR78","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.ymthe.2017.01.024","volume":"25","author":"A Hall","year":"2017","unstructured":"Hall A, L\u00e4chelt U, Bartek J, Wagner E, Moghimi SM. Polyplex evolution: understanding biology, optimizing performance. Mol Ther: J Am Soc Gene Ther. 2017;25:1476\u201390.","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"key":"469_CR79","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1080\/10717544.2018.1510065","volume":"25","author":"H Zhang","year":"2018","unstructured":"Zhang H, Chen Z, Du M, Li Y, Chen Y. Enhanced gene transfection efficiency by low-dose 25\u2009kDa polyethylenimine by the assistance of 1.8\u2009kDa polyethylenimine. Drug Deliv. 2018;25:1740\u20135.","journal-title":"Drug Deliv"},{"key":"469_CR80","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.3390\/cells10081896","volume":"10","author":"JY Lee","year":"2021","unstructured":"Lee JY, Hong JW, Thambi T, Yoon A-R, Choi J-W, Li Y, et al. Optimizing active tumor targeting biocompatible polymers for efficient systemic delivery of adenovirus. Cells. 2021;10:1896.","journal-title":"Cells"},{"key":"469_CR81","first-page":"23","volume":"1","author":"V Kafil","year":"2011","unstructured":"Kafil V, Omidi Y. Cytotoxic impacts of linear and branched polyethylenimine nanostructures in a431 cells. Bioimpacts. 2011;1:23\u201330.","journal-title":"Bioimpacts"},{"key":"469_CR82","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1021\/acs.biomac.5b00538","volume":"16","author":"J-W Choi","year":"2015","unstructured":"Choi J-W, Nam J-P, Nam K, Lee YS, Yun C-O, Kim SW. Oncolytic adenovirus coated with multidegradable bioreducible core-cross-linked polyethylenimine for cancer gene therapy. Biomacromolecules. 2015;16:2132\u201343.","journal-title":"Biomacromolecules"},{"key":"469_CR83","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1021\/bm501116x","volume":"16","author":"S-J Jung","year":"2015","unstructured":"Jung S-J, Kasala D, Choi J-W, Lee S-H, Hwang JK, Kim SW, et al. Safety profiles and antitumor efficacy of oncolytic adenovirus coated with bioreducible polymer in the treatment of a CAR negative tumor model. Biomacromolecules. 2015;16:87\u201396.","journal-title":"Biomacromolecules"},{"key":"469_CR84","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1021\/bc700397x","volume":"19","author":"M Ou","year":"2008","unstructured":"Ou M, Wang X-L, Xu R, Chang C-W, Bull DA, Kim SW. Novel biodegradable poly(disulfide amine)s for gene delivery with high efficiency and low cytotoxicity. Bioconjugate Chem. 2008;19:626\u201333.","journal-title":"Bioconjugate Chem"},{"key":"469_CR85","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jconrel.2019.04.040","volume":"305","author":"Y Na","year":"2019","unstructured":"Na Y, Nam J-P, Hong J, Oh E, Shin HC, Kim HS, et al. Systemic administration of human mesenchymal stromal cells infected with polymer-coated oncolytic adenovirus induces efficient pancreatic tumor homing and infiltration. J Controlled Release. 2019;305:75\u201388.","journal-title":"J Controlled Release"},{"key":"469_CR86","doi-asserted-by":"publisher","first-page":"13058","DOI":"10.1021\/acsami.8b21185","volume":"11","author":"HTT Duong","year":"2019","unstructured":"Duong HTT, Thambi T, Yin Y, Lee JE, Seo YK, Jeong JH, et al. Smart pH-responsive nanocube-controlled delivery of DNA vaccine and chemotherapeutic drugs for chemoimmunotherapy. ACS Appl Mater Interfaces. 2019;11:13058\u201368.","journal-title":"ACS Appl Mater Interfaces"},{"key":"469_CR87","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jconrel.2015.01.005","volume":"205","author":"J-W Choi","year":"2015","unstructured":"Choi J-W, Jung S-J, Kasala D, Hwang JK, Hu J, Bae YH, et al. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis. J Controlled Release. 2015;205:134\u201343.","journal-title":"J Controlled Release"},{"key":"469_CR88","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.actbio.2015.09.014","volume":"28","author":"J-W Choi","year":"2015","unstructured":"Choi J-W, Dayananda K, Jung S-J, Lee S-H, Kim D, Hu J, et al. Enhanced anti-tumor efficacy and safety profile of tumor microenvironment-responsive oncolytic adenovirus nanocomplex by systemic administration. Acta Biomaterialia. 2015;28:86\u201398.","journal-title":"Acta Biomaterialia"},{"key":"469_CR89","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/adhm.201500618","volume":"4","author":"CS Verbeke","year":"2015","unstructured":"Verbeke CS, Mooney DJ. Injectable, pore-forming hydrogels for in vivo enrichment of immature dendritic cells. Adv Healthc Mater. 2015;4:2677\u201387.","journal-title":"Adv Healthc Mater"},{"key":"469_CR90","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jconrel.2010.06.027","volume":"148","author":"Y Park","year":"2010","unstructured":"Park Y, Kang E, Kwon O-J, Hwang T, Park H, Lee JM, et al. Ionically crosslinked Ad\/chitosan nanocomplexes processed by electrospinning for targeted cancer gene therapy. J Controlled Release. 2010;148:75\u201382.","journal-title":"J Controlled Release"},{"key":"469_CR91","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jconrel.2013.03.030","volume":"169","author":"O-J Kwon","year":"2013","unstructured":"Kwon O-J, Kang E, Choi J-W, Kim SW, Yun C-O. Therapeutic targeting of chitosan\u2013PEG\u2013folate-complexed oncolytic adenovirus for active and systemic cancer gene therapy. J Controlled Release. 2013;169:257\u201365.","journal-title":"J Controlled Release"},{"key":"469_CR92","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jconrel.2016.02.046","volume":"231","author":"AR Yoon","year":"2016","unstructured":"Yoon AR, Kasala D, Li Y, Hong J, Lee W, Jung S-J, et al. Antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with EGFR-targeted PAMAM-based dendrimer in orthotopic lung tumor model. J Controlled Release. 2016;231:2\u201316.","journal-title":"J Controlled Release"},{"key":"469_CR93","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41416-019-0495-5","volume":"121","author":"CR Ireson","year":"2019","unstructured":"Ireson CR, Alavijeh MS, Palmer AM, Fowler ER, Jones HJ. The role of mouse tumour models in the discovery and development of anticancer drugs. Br J Cancer. 2019;121:101\u20138.","journal-title":"Br J Cancer"},{"key":"469_CR94","doi-asserted-by":"publisher","first-page":"5158","DOI":"10.1016\/j.biomaterials.2011.03.084","volume":"32","author":"J Kim","year":"2011","unstructured":"Kim J, Nam HY, Kim T-I, Kim P-H, Ryu J, Yun C-O, et al. Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA. Biomaterials. 2011;32:5158\u201366.","journal-title":"Biomaterials"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-022-00469-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-022-00469-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-022-00469-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T23:05:58Z","timestamp":1666047958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-022-00469-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":94,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["469"],"URL":"https:\/\/doi.org\/10.1038\/s41417-022-00469-y","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"assertion":[{"value":"16 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}